TGFB1 and keratoacanthoma: However, the translational potential for direct TGF-β blockade is unclear, as the direct TGF-β blockade with the monoclonal antibody fresolimumab has been associated with adverse effects like keratoacanthomas in clinical trials for non-cardiac indications [64].